Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that the U.S. Food and Drug Administration has cleared Investigational New Drug applications for the Company's two most advanced product candidates, AB928 and AB122.
More...